Joe M. McCord

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Joe Milton McCord
BornMarch 3, 1945 (1945-03-03) (age 73)
ResidenceDenver, Colorado
CitizenshipUnited States
Alma materRhodes College, Duke University
Known forDiscovery of superoxide dismutase
Scientific career
FieldsBiochemistry
InstitutionsUniversity of Colorado
Doctoral advisorIrwin Fridovich

Joe Milton McCord (born March 3, 1945) is an American biochemist. While serving as a graduate student, he and his supervisor Irwin Fridovich were the first to describe the enzymatic activity of superoxide dismutase.[1][2] McCord joined the board of directors of the LifeVantage Corporation (makers of the dietary supplement Protandim) in 2006, serving as the company's chief science officer from 2011 to 2012, and retired from the company in June 2013.[3]

Academic Background[edit]

McCord received a B.S. degree in chemistry from Rhodes College (graduated 1966) and a Ph.D. in biochemistry from Duke University (graduated 1970), where he also conducted postdoctoral research.[citation needed]

McCord is a past recipient of the Elliott Cresson Medal, the Discovery Award from the Society for Free Radical Biology and Medicine (SFRBM),[4][not in citation given] and a Lifetime Achievement Award from the Oxygen Society.[citation needed]

LifeVantage/Protandim[edit]

McCord served on the board of directors (Director of Science) of the LifeVantage Corporation beginning in 2006[5] and was listed by the SEC as an insider shareholder.[6] LifeVantage is a Utah-based multilevel marketing company that distributes an antioxidant dietary supplement known as Protandim. McCord co-authored 7 studies on the product[7][8][9][10][11][12][13] and participated in distributor training.[6] McCord served as Chief Scientific Officer for LifeVantage from June 2011 until September 2012, and then became a member of the company's science advisory board. LifeVantage announced McCord’s retirement in June 2013.[3][14] Under the terms of the separation agreement, McCord was to receive a payment of $1.7 million from the company.[14]

Pathways Bioscience[edit]

McCord co-founded the company Pathways Bioscience in 2014, where he is currently leading research on gene expression and aging.[15][16]

References[edit]

  1. ^ McCord JM, Fridovich I (November 1969). "Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein)". J. Biol. Chem. 244 (22): 6049–55. PMID 5389100.
  2. ^ Keele BB, McCord JM, Fridovich I (November 1970). "Superoxide dismutase from escherichia coli B. A new manganese-containing enzyme". J. Biol. Chem. 245 (22): 6176–81. PMID 4921969.
  3. ^ a b http://globenewswire.com/news-release/2013/06/25/556132/10037495/en/Dr-Joe-McCord-LifeVantage-Corporation-s-First-Chief-Science-Officer-Retires-From-Company.html[full citation needed]
  4. ^ "SFRBM - Society for Free Radical Biology and Medicine".
  5. ^ http://www.allbusiness.com/company-activities-management/board-management/5376294-1.html[full citation needed]
  6. ^ a b http://secwatch.com/mccord-joe-m[full citation needed]
  7. ^ Nelson SK, Bose SK, Grunwald GK, Myhill P, McCord JM (January 2006). "The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy". Free Radic. Biol. Med. 40 (2): 341–7. doi:10.1016/j.freeradbiomed.2005.08.043. PMID 16413416.
  8. ^ Velmurugan K, Alam J, McCord JM, Pugazhenthi S (February 2009). "Synergistic induction of heme oxygenase-1 by the components of the antioxidant supplement Protandim". Free Radic. Biol. Med. 46 (3): 430–40. doi:10.1016/j.freeradbiomed.2008.10.050. PMID 19056485.
  9. ^ Liu J, Gu X, Robbins D, et al. (2009). "Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a model". PLoS ONE. 4 (4): e5284. doi:10.1371/journal.pone.0005284. PMC 2668769. PMID 19384424.
  10. ^ Robbins D, Gu X, Shi R, et al. (2010). "The chemopreventive effects of Protandim: modulation of p53 mitochondrial translocation and apoptosis during skin carcinogenesis". PLoS ONE. 5 (7): e11902. doi:10.1371/journal.pone.0011902. PMC 2912769. PMID 20689586.
  11. ^ Bogaard HJ, Natarajan R, Henderson SC, et al. (November 2009). "Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure". Circulation. 120 (20): 1951–60. doi:10.1161/CIRCULATIONAHA.109.883843. PMID 19884466.
  12. ^ Qureshi MM, McClure WC, Arevalo NL, et al. (June 2010). "The Dietary Supplement Protandim Decreases Plasma Osteopontin and Improves Markers of Oxidative Stress in Muscular Dystrophy Mdx Mice". J Diet Suppl. 7 (2): 159–178. doi:10.3109/19390211.2010.482041. PMC 2926985. PMID 20740052.
  13. ^ Joddar B, Reen RK, Firstenberg MS, et al. (March 2011). "Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway". Free Radic. Biol. Med. 50 (6): 700–9. doi:10.1016/j.freeradbiomed.2010.12.008. PMID 21167278.
  14. ^ a b "Form 8-K for LifeVantage Corp". Yahoo.com. June 25, 2013. Retrieved 11/10/2013. Check date values in: |accessdate= (help)
  15. ^ http://www.prweb.com/releases/2018/05/prweb15494949.htm
  16. ^ http://www.prweb.com/releases/2017/05/prweb14312145.htm

External links[edit]